1. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Issue 5 (May 2023) Authors: Howard, James F; Bresch, Saskia; Genge, Angela; Hewamadduma, Channa; Hinton, John; Hussain, Yessar; Juntas-Morales, Raul; Kaminski, Henry J; Maniaol, Angelina; Mantegazza, Renato; Masuda, Masayuki; Sivakumar, Kumaraswamy; Śmiłowski, Marek; Utsugisawa, Kimiaki; Vu, Tuan; Weiss, Michael D; Zajda, M... Journal: Lancet neurology Issue: Volume 22:Issue 5(2023) Page Start: 395 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Issue 7 (July 2021) Authors: Howard, James F; Bril, Vera; Vu, Tuan; Karam, Chafic; Peric, Stojan; Margania, Temur; Murai, Hiroyuki; Bilinska, Malgorzata; Shakarishvili, Roman; Smilowski, Marek; Guglietta, Antonio; Ulrichts, Peter; Vangeneugden, Tony; Utsugisawa, Kimiaki; Verschuuren, Jan; Mantegazza, Renato; De Bleecker, Jan... Journal: Lancet neurology Issue: Volume 20:Issue 7(2021) Page Start: 526 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗